JP2010501191A5 - - Google Patents

Download PDF

Info

Publication number
JP2010501191A5
JP2010501191A5 JP2009525967A JP2009525967A JP2010501191A5 JP 2010501191 A5 JP2010501191 A5 JP 2010501191A5 JP 2009525967 A JP2009525967 A JP 2009525967A JP 2009525967 A JP2009525967 A JP 2009525967A JP 2010501191 A5 JP2010501191 A5 JP 2010501191A5
Authority
JP
Japan
Prior art keywords
fusion protein
component
nucleic acid
protein according
iii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009525967A
Other languages
English (en)
Japanese (ja)
Other versions
JP5274464B2 (ja
JP2010501191A (ja
Filing date
Publication date
Priority claimed from EP06017891A external-priority patent/EP1894940A1/en
Application filed filed Critical
Publication of JP2010501191A publication Critical patent/JP2010501191A/ja
Publication of JP2010501191A5 publication Critical patent/JP2010501191A5/ja
Application granted granted Critical
Publication of JP5274464B2 publication Critical patent/JP5274464B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009525967A 2006-08-28 2007-08-28 Tnfスーパーファミリー融合タンパク質 Expired - Fee Related JP5274464B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06017891.0 2006-08-28
EP06017891A EP1894940A1 (en) 2006-08-28 2006-08-28 TNF superfamily fusion proteins
PCT/EP2007/007517 WO2008025516A2 (en) 2006-08-28 2007-08-28 Tnf superfamily fusion proteins

Publications (3)

Publication Number Publication Date
JP2010501191A JP2010501191A (ja) 2010-01-21
JP2010501191A5 true JP2010501191A5 (https=) 2010-07-15
JP5274464B2 JP5274464B2 (ja) 2013-08-28

Family

ID=37836940

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009525967A Expired - Fee Related JP5274464B2 (ja) 2006-08-28 2007-08-28 Tnfスーパーファミリー融合タンパク質

Country Status (8)

Country Link
US (2) US8147843B2 (https=)
EP (2) EP1894940A1 (https=)
JP (1) JP5274464B2 (https=)
AT (1) ATE505481T1 (https=)
AU (1) AU2007291490A1 (https=)
CA (2) CA2860945C (https=)
DE (1) DE602007013920D1 (https=)
WO (1) WO2008025516A2 (https=)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2560871T3 (es) 2007-07-10 2016-02-23 Apogenix Gmbh Proteínas de fusión de colectina de la superfamilia de TNF
WO2010003766A2 (en) * 2008-06-17 2010-01-14 Apogenix Gmbh Multimeric tnf receptors
WO2010006772A2 (en) * 2008-07-14 2010-01-21 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Use of cd95 inhibitors for the treatment of inflammatory disorders
ES2538122T3 (es) 2008-07-21 2015-06-17 Apogenix Gmbh Moléculas de una sola cadena de TNFSF
US8664366B2 (en) 2009-01-09 2014-03-04 Apogenix Gmbh Fusion proteins forming trimers
TWI476001B (zh) 2011-12-26 2015-03-11 Ind Tech Res Inst 三倍體Fc融合蛋白及其用途
BR112015001390B1 (pt) 2012-07-26 2024-04-30 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc Proteína de fusão, ácido nucleico isolado e uso de uma composição de vacina
WO2014100913A1 (en) * 2012-12-24 2014-07-03 Beijing Anxinhuaide Biotech. Co., Ltd Improving the half life of a therapeutic polypeptide by fusing with a trimeric scaffold protein via a spacer
NO2776305T3 (https=) 2014-04-23 2018-01-27
BR102014031185A8 (pt) * 2014-12-12 2021-05-04 Fund De Amparo A Pesquisa Do Estado De Sao Paulo Fapesp proteína recombinante indutora da apoptose; processo de obtenção da dita proteína e o seu uso no tratamento do câncer
IL308212A (en) 2015-01-20 2024-01-01 Igm Biosciences Inc Tumor necrosis factor-α receptor binding molecules and their uses
MA41460A (fr) 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
EP3076179A1 (en) 2015-03-30 2016-10-05 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Diagnosis and treatment of low grade gliomas
CN108290950B (zh) 2015-09-23 2022-01-28 阿珀吉科吉尼科斯股份公司 抗cd95l抗体
EP3374504B1 (en) * 2015-11-09 2025-03-19 CureVac SE Optimized nucleic acid molecules
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
MX2019007963A (es) 2017-01-06 2019-10-21 Iovance Biotherapeutics Inc Expansion de linfocitos infiltrantes de tumor (til) con agonistas de la superfamilia de recptor de factor de necrosis tumoral (tnfrsf) y combinaciones terapeuticas de til- y agonistas de tnfrsf.
CA3049165A1 (en) 2017-01-06 2018-07-12 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
KR20200003913A (ko) 2017-05-10 2020-01-10 이오반스 바이오테라퓨틱스, 인크. 액상 종양으로부터의 종양 침윤 림프구의 확장 및 그의 치료 용도
AR112072A1 (es) 2017-06-05 2019-09-18 Iovance Biotherapeutics Inc Métodos de uso de linfocitos infiltrantes de tumor en melanoma doble refractario
JP7744621B2 (ja) * 2017-08-11 2025-09-26 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイ 切断されたモルモットl-アスパラギナーゼバリアントおよび使用の方法
CR20200251A (es) 2017-11-17 2020-07-17 Iovance Biotherapeutics Inc Expansión de til de aspirados con aguja fina y biopsias por punción
EP3714041A1 (en) 2017-11-22 2020-09-30 Iovance Biotherapeutics, Inc. Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
US20210369775A1 (en) 2017-12-15 2021-12-02 Iovance Biotherapeutics, Inc. Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof
WO2019136459A1 (en) 2018-01-08 2019-07-11 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
US11713446B2 (en) 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
EP3737743A1 (en) 2018-01-08 2020-11-18 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
CA3090795A1 (en) 2018-02-13 2019-08-22 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists
CA3094957A1 (en) 2018-03-29 2019-10-03 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
WO2019210131A1 (en) 2018-04-27 2019-10-31 Iovance Biotherapeutics, Inc. Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
WO2019217753A1 (en) 2018-05-10 2019-11-14 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
WO2020018715A1 (en) 2018-07-17 2020-01-23 Massachusetts Institute Of Technology Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof
TW202031273A (zh) 2018-08-31 2020-09-01 美商艾歐凡斯生物治療公司 抗pd-1抗體難治療性之非小細胞肺癌(nsclc)病患的治療
IL281423B2 (en) 2018-09-20 2024-08-01 Iovance Biotherapeutics Inc Expansion of TILS from cryopreserved tumor samples
WO2020096927A1 (en) 2018-11-05 2020-05-14 Iovance Biotherapeutics, Inc. Expansion of tils utilizing akt pathway inhibitors
MY210603A (en) 2018-11-05 2025-10-01 Iovance Biotherapeutics Inc Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
US12611427B2 (en) 2018-11-05 2026-04-28 Iovance Biotherapeutics, Inc. Treatment of NSCLC patients refractory for anti-PD-1 antibody
JP7854297B2 (ja) 2018-11-05 2026-05-01 アイオバンス バイオセラピューティクス,インコーポレイテッド 改良された腫瘍反応性t細胞の選択
CA3123392A1 (en) 2018-12-19 2020-06-25 Iovance Biotherapeutics, Inc. Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof
WO2020180733A1 (en) 2019-03-01 2020-09-10 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
US20220177841A1 (en) 2019-03-29 2022-06-09 Myst Therapeutics Llc Ex vivo methods for producing a t cell therapeutic and related compositions and methods
WO2020232029A1 (en) 2019-05-13 2020-11-19 Iovance Biotherapeutics, Inc. Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
EP4048295A1 (en) 2019-10-25 2022-08-31 Iovance Biotherapeutics, Inc. Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
US20230032934A1 (en) 2019-11-27 2023-02-02 Myst Therapeutics, Llc Method of producing tumor-reactive t cell composition using modulatory agents
US12516291B2 (en) 2019-12-11 2026-01-06 Iovance Biotherapeutics, Inc. Processes for the production of tumor infiltrating lymphocytes (TILs) and methods of using the same
EP4512828A3 (en) 2020-02-27 2025-05-14 Turnstone Biologics Corp. Methods for ex vivo enrichment and expansion of tumor reactive t cells and related compositions thereof
CA3176826A1 (en) 2020-05-04 2021-11-11 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
CA3177413A1 (en) 2020-05-04 2021-11-11 Michelle SIMPSON-ABELSON Selection of improved tumor reactive t-cells
US20240016918A1 (en) * 2020-08-24 2024-01-18 Sanofi Pasteur Inc. Vaccines against sars-cov-2 infections
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
JP2023546359A (ja) 2020-10-06 2023-11-02 アイオバンス バイオセラピューティクス,インコーポレイテッド 腫瘍浸潤リンパ球療法によるnsclc患者の治療
EP4259164A1 (en) 2020-12-11 2023-10-18 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors
EP4262827A1 (en) 2020-12-17 2023-10-25 Iovance Biotherapeutics, Inc. Treatment of cancers with tumor infiltrating lymphocytes
AU2021401302A1 (en) 2020-12-17 2023-07-06 Iovance Biotherapeutics, Inc. Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
CA3207359A1 (en) 2021-02-05 2022-08-11 Cecile Chartier-Courtaud Adjuvant therapy for cancer
EP4301138A2 (en) 2021-03-05 2024-01-10 Iovance Biotherapeutics, Inc. Tumor storage and cell culture compositions
JP2024512029A (ja) 2021-03-25 2024-03-18 アイオバンス バイオセラピューティクス,インコーポレイテッド T細胞共培養効力アッセイのための方法及び組成物、ならびに細胞療法製品との使用
CA3215830A1 (en) 2021-04-19 2022-10-27 Rafael CUBAS Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
JP2024519029A (ja) 2021-05-17 2024-05-08 アイオバンス バイオセラピューティクス,インコーポレイテッド Pd-1遺伝子編集された腫瘍浸潤リンパ球及び免疫療法におけるその使用
KR20240013766A (ko) * 2021-05-27 2024-01-30 베이징 안신화이더 바이오텍. 씨오., 엘티디 2개의 trail 삼량체를 포함하는 수퍼-trail 분자
JP2024527961A (ja) 2021-07-28 2024-07-26 アイオバンス バイオセラピューティクス,インコーポレイテッド Kras阻害剤と併用した腫瘍浸潤リンパ球療法によるがん患者の治療
US20250000903A1 (en) 2021-09-24 2025-01-02 Iovance Biotherapeutics, Inc. Expansion processes and agents for tumor infiltrating lymphocytes
WO2023077015A2 (en) 2021-10-27 2023-05-04 Iovance Biotherapeutics, Inc. Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
CA3237410A1 (en) 2021-11-10 2023-05-19 Friedrich Graf Finck VON FINCKENSTEIN Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
CA3243416A1 (en) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. TUMOR INFILTRATION LYMPHOCYTES MODIFIED TO EXPRESS PAYLOADS
JP2025512401A (ja) 2022-04-15 2025-04-17 アイオバンス バイオセラピューティクス,インコーポレイテッド 特定のサイトカインの組み合わせ及び/またはAKTi処理を使用したTIL拡張プロセス
US20260021181A1 (en) 2022-08-01 2026-01-22 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
WO2024098024A1 (en) 2022-11-04 2024-05-10 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
WO2024151885A1 (en) 2023-01-13 2024-07-18 Iovance Biotherapeutics, Inc. Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy
WO2025101484A1 (en) 2023-11-06 2025-05-15 Iovance Biotherapeutics, Inc. Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2410525A1 (en) * 2000-05-26 2001-11-29 Mochida Pharmaceuticals Co., Ltd. Fas ligand-fused proteins

Similar Documents

Publication Publication Date Title
JP2010501191A5 (https=)
US12060401B2 (en) Compositions and methods for treatment of autoimmune and inflammatory diseases and disorders
JP7128246B2 (ja) 抗炎症活性を有するペプチド、及びそれを含む組成物
JP6545759B2 (ja) アゴニストおよびアンタゴニストとしての循環置換により修飾されるリガンド
CN100385002C (zh) 重组融合蛋白的二聚体、三聚体、四聚体或五聚体的二聚物或寡聚物
JP5274464B2 (ja) Tnfスーパーファミリー融合タンパク質
EP3998077B1 (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
JP2021501581A5 (https=)
JP6038816B2 (ja) 新規な超活性il−33断片およびその使用
HRP20150425T1 (hr) Tnf sf jednolanäśane molekule
FI3368555T3 (fi) Kaksitoimisia proteiineja ja niitä sisältävä farmaseuttinen koostumus
WO2009149171A4 (en) Fgf21 mutants and uses thereof
CN104470944A (zh) 非天然共有白蛋白结合结构域
JP2018533947A5 (https=)
Yuan et al. Production of recombinant human interleukin-38 and its inhibitory effect on the expression of proinflammatory cytokines in THP-1 cells
CA2894219C (en) Novel interleukin-33 inhibitors
JP2020519230A5 (https=)
JP5462623B2 (ja) Elr−cxcケモカインの高親和性アンタゴニスト
JP6320973B2 (ja) B細胞活性化因子の拮抗物質、その調製方法及び利用法
US7820622B2 (en) TNF antagonists
KR101955366B1 (ko) 인터페론 베타-엘라스틴 재조합 단백질 및 이의 생산방법
Pyo et al. Expression and purification of a recombinant buforin derivative from Escherichia coli
EP2597102A1 (en) A novel fusion protein comprising an antibody light chain and a polypeptide binding to IL-17
JP2009536821A5 (https=)
JP5385611B2 (ja) Pf4とrantesとの相互作用に対するアンタゴニスト